Skip To Main Content

Exec Edge

All articles publish immediately here as well as Yahoo Finance through a content partnership. We have a similar agreement with Bloomberg where article links appear on Bloomberg Terminals at {NH CMD <GO>}. Both platforms also publish our content under any relevant public company tickers. Exec Edge spotlights senior executives, advisors, entrepreneurs, and others who share their perspectives on effective business leadership and management. Content takes the form of Q&As, bylined articles, and original commentary. The platform is designed for leaders at both public and private companies. Source

Actions

Share this page

Media Outlet details

Scope N/A
Language English
Country N/A
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

Sir Lynton Crosby, CT Group Executive Chairman, on the Case for Capitalism

| Exec Edge
By Exec-Edge Editorial Staff Sir Lynton Crosby has spent four decades reading public opinion for people who couldn’t afford to get it wrong — prime ministers, presidents, and the boards of some of the world’s largest companies.
Open in Who Shared View Duplicates (2) Issue with article?

Time to Build Better Corporate Governance at BETR

| Exec Edge
Better Home & Finance Holding Co. (Nasdaq: BETR) ousted founder & CEO Vishal Garg in early August coup led by interim replacement, Orange Capital Managing Partner Daniel Lewis Better Home implemented poison pill on Aug.
Open in Who Shared View Duplicates (3) Issue with article?

Swarmer Targets $200M in Pro Forma Revenue Next Year – Report

| Exec Edge
By Karen Roman Swarmer, Inc.’s (Nasdaq: SWMR) pending acquisition ofUkrainian unmanned-ground-vehicle maker Ratel Robotics could lead to $200 million in 2027 revenue and $20 million in adjusted EBITDA, according to a research note by Lucid Capital Markets.
Open in Who Shared View Duplicates (2) Issue with article?

Slate Medicines Names Kenneth Koblan as Chief Scientific Officer

| Exec Edge
By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head of Development Operations.
Open in Who Shared View Duplicates (2) Issue with article?

U.S. Anesthesia Partners Leads a Changing Industry by Preparing the Next Generation for the Future of Anesthesia

| Exec Edge
By Neal Grabarkewitz Every September, a select group of physician residents and student nurse anesthetists gather in Austin for U.S. Anesthesia Partners’ Future Leaders in Anesthesia conference. This year, we rebuilt large parts of it. The reason comes down to a simple fact: the job these students are training for looks different than it did even three years ago, and the way we prepare them for it needs to change too.
Open in Who Shared View Duplicates (2) Issue with article?

Reformation Reports Double-Digit Income & Revenue Growth

| Exec Edge
By Karen Roman Reformation Inc. (NYSE: REF) said net revenue rose 24.1% to $155.2 million compared to the year prior driven by strength across channels, and net income increased 79.4% to $12.4 million or $0.23 per diluted share. Adjusted EBITDA grew 53.9% to $25.4 million with margin expanding 320 basis points to 16.4%, while gross margin increased 230 basis points to 66.7%, it stated.
Open in Who Shared View Duplicates (2) Issue with article?

VERAXA Biotech Designates Raju Willener as CFO

| Exec Edge
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of the biopharmaceutical development process, the company stated.
Open in Who Shared View Duplicates (2) Issue with article?

Lands’ End New CEO Agenda, Customer Growth – Quarterly Update Report

| Exec Edge
Download the Complete Report Here Key Takeaways: New CEO Charlie Cole is sharpening the growth agenda around digital execution, AI-enabled customer engagement and stronger operating infrastructure. 2Q revenue increased 2.7% y/y as fulfilment normalized; U.S. eCommerce growth included shipment catch-up and remains approximately flat YTD. New-to-file customers grew double digits, social traffic rose over 30%, and franchise strength in totes and swim is supporting customer acquisition.
Open in Who Shared View Duplicates (2) Issue with article?

Lands’ End New CEO Agenda, Customer Growth – Downloadable Quarterly Update Report

| Exec Edge
Download the Complete Report Here Lands’ End, Inc. (LE) Fulfilment Normalizes as New CEO...
Open in Who Shared Issue with article?

REX’s Record 2Q EPS, CCS Project Advances – Quarterly Update Report

| Exec Edge
Download the Complete Report Here Record Second Quarter Driven by Stronger Crush Margins and 45Z; Draft Class VI Permits Advance CCS Project; Valuation Remains Reasonable Key Takeaways: Record 2Q EPS of $1.06 versus $0.22 y/y, as stronger crush economics and 45Z drove gross profit to $53.3 million and gross margin to 31.6%, up ~2,260 bps. 45Z income increased to $18.4 million from $7.5 million sequentially, lifting first-half credits to $26.0 million and strengthening gross profit.
Open in Who Shared View Duplicates (2) Issue with article?

Exec Edge Journalists

Banks, Jarrett